Verition Fund Management
ORMP icon

Verition Fund Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Verition Fund Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,550
Closed -$44.8K – 2445
2023
Q1 		$44.8K Buy
+20,550
New +$65.3K ﹤0.01% 1970

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Verition Fund Management's ORMP Position: Q2 2023 in Review

Verition Fund Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2023, closing a stake of 20,550 shares — an estimated $44.8K sold.

Verition Fund Management first reported a position in ORMP in Q1 2023 and held it in 1 quarter. The position peaked at $44.8K in Q1 2023. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

  • Verition Fund Management reported no remaining Oramed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Verition Fund Management sold 20,550 Oramed Pharmaceuticals shares in Q2 2023, an estimated $44.8K.
  • Verition Fund Management first reported a position in Oramed Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Verition Fund Management's Oramed Pharmaceuticals position peaked at $44.8K in Q1 2023.
  • 50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on Verition Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.